George Hartman
Chemistry adviser
George D. Hartman, Ph.D., is the co-founder and vice president of chemistry and pre-clinical development of Novira Therapeutics. Prior to this role, Dr. Hartman was at Merck for over 35 years, rising to the level of executive director of medicinal chemistry, where he was responsible for the discovery and development of clinical candidates across multiple therapeutic areas, including cancer, schizophrenia, insomnia, Parkinson’s, inflammation, ophthalmics and anti-infectives. Dr. Hartman was the lead inventor for Aggrastat®, an anti-platelet agent used worldwide in the treatment of ischemic coronary disease.
In addition, he and his group identified and brought to the clinic 12 drug candidates that have been evaluated in Phase 2 or Phase 3 trials. When he retired from Merck in 2008, Dr. Hartman had responsibility for over 120 researchers across key project areas. He is an author or co-author on more than 170 peer-reviewed papers and more than 130 issued U.S. patents, lectured at U.S. and foreign universities, and has given more than 40 invited talks. Dr. Hartman is the past chair of the Gordon Conference on Medicinal Chemistry, has organized more than 20 symposia and conferences and held the position of editor of ChemMedChem.
Dr. Hartman holds a doctorate in organic chemistry from The Ohio State University.